Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

0.9735 +0.1645 (+20.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
News headline image
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket ↗
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday. 
Via Benzinga
News headline image
Longeveron's Return On Capital Employed Insights ↗
Longeveron (NASDAQ:LGVN) brought in sales totaling $466 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 60.23%, resulting in a loss of $5.62 million. 
Via Benzinga
News headline image
PFE, MRNA Stocks: What to Know as the FDA Approves New Booster Shots ↗
Pfizer (PFE) and Moderna (MRNA) stocks are in the news Wednesday as the FDA approves new booster shots for the Covid-19 Omicron variant. 
Via InvestorPlace
News headline image
Why Is Longeveron (LGVN) Stock on the Move Today? ↗
Longeveron (LGVN) stock is on the move Wednesday after the FDA granted its fast-track designation for heart treatment Lomecel-B. 
Via InvestorPlace
News headline image
Longeveron: Q2 Earnings Insights ↗
  Longeveron (NASDAQ:LGVN) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: Longeveron Q1 Earnings ↗
Longeveron (NASDAQ:LGVN) reported its Q1 earnings results on Friday, May 13, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Longeveron Shares Ascend As FDA Grants Fast Track Status To Congenital Heart Disease Candidate ↗
Longeveron (NASDAQ: LGVN) received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS). 
Via Benzinga
News headline image
EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants ↗
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart... 
Via Benzinga
News headline image
European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy ↗
Longeveron Inc. (NASDAQ: LGVN) announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No. 
Via Benzinga
News headline image
EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent ↗
The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2022 ↗
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
News headline image
Longeveron Earnings Preview ↗
  Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will... 
Via Benzinga
News headline image
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry? ↗
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. 
Via Benzinga
News headline image
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron ↗
Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN) 
Via Benzinga
News headline image
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment ↗
The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty. 
Via Benzinga
News headline image
7 Moonshot Investments Upending a $10 Trillion Industry ↗
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
News headline image
Why U.S. Stocks Are Trading Higher After Rise In Jobless Claims ↗
U.S. stocks traded higher this morning, following the release of data on initial jobless claims. 
Via Benzinga
News headline image
7 Ways to Prepare for a Recession: An Investor’s Guide ↗
There are plenty of ways to prepare for a recession. Here are seven ways you can make sure you're ready for whatever comes next. 
Via InvestorPlace
News headline image
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday ↗
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
News headline image
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It ↗
Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. 
Via Benzinga
News headline image
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp. 
Via Benzinga
News headline image
How to Buy Stocks in a Recession ↗
The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2022 ↗
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million. 
Via Benzinga
News headline image
Longeveron's Earnings: A Preview ↗
Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-05-13. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
With the start of another day comes our breakdown of the biggest pre-market stock movers and this time it's for Thursday! 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Follow the Insiders and Buy the Dip in These 3 Stocks ↗
These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments. 
Via InvestorPlace
News headline image
71 Biggest Movers From Yesterday ↗
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.